Introduction
Sphingolipids comprise a family of bioactive lipids that exert antagonizing roles in diverse cellular functions such as cell proliferation, growth arrest or apoptosis (Kolesnick, 2002; Spiegel and Milstien, 2003; Ogretmen and Hannun, 2004) . Ceramide has been identified as a cell death effector and its generation has been shown to increase in response to apoptotic stimuli (e.g. stress, death ligands, radiation or chemotherapy) before cell death (Kolesnick and Kronke, 1998; Ogretmen and Hannun, 2004 ). Ceramide has been described to activate various cell death mechanisms including mitochondrial recruitment (Kolesnick, 2002) . For instance, through interaction with mitochondria, ceramide elicits a burst of reactive oxygen species (ROS) and release of mitochondrial apoptotic proteins, thus engaging the mitochondrial apoptosome (Garcia-Ruiz et al., 1997; Quillet-Mary et al., 1997; Ghafourifar et al., 1999) . Other sphingolipids with death-promoting activity include gangliosides, such as ganglioside GD3, which has been shown to mediate apoptosis by a dual mechanism involving interaction with mitochondria and suppression of survival pathways (Scorrano et al., 1999; Garcia-Ruiz et al., 2000; Rippo et al., 2000; Colell et al., 2001; Paris et al., 2002a) . In contrast, sphingosine-1-phosphate (S1P) has been mainly characterized as an antiapoptotic lipid, mediating cell proliferation and survival (Cuvillier et al., 1996; Olivera et al., 1999; Paris et al., 2002b) . The role of sphingosine in cell death regulation, however, is less clear and has been described both as a proapoptotic (Suzuki et al., 2004) or antiapoptotic (Monick et al., 2004) intermediate. Thus, the relative balance in the generation of pro-vs antiapoptotic sphingolipids may determine the fate of cells in response to cell death stimuli.
Ceramide can be generated through several pathways such as its de novo synthesis from L-serine and palmitoyl coenzyme A or by sphingomyelin hydrolysis upon activation of sphingomyelinases (SMases) (Kolesnick, 2002; Garcia-Ruiz et al., 2003; Ogretmen and Hannun, 2004) . However, the metabolism of ceramide can limit its accumulation, and hence its participation in death pathways. Ceramide, in addition to its transformation into glucosylceramide, the precursor of gangliosides, through glucosylceramide synthase (GCS), can be deacylated by ceramidases (CDases) into sphingosine. The phosphorylation of sphingosine by sphingosine kinase (SK) generates S1P, and thus CDases coupled with SK contribute to the conversion of ceramide into the antiapoptotic intermediate S1P.
Three ceramidase (CDase) isoforms with distinctive pH optimums, acid, alkaline and neutral, have been described (Hassler and Bell, 1993) and their relative contribution to cell death seems to be dependent on the stimuli and the cell type studied. For instance, the neutral CDase has been shown to play a protective role against cytokine-induced cell death in mesangial cells (Franzen et al., 2001) , whereas the overexpression of acid CDase protected L929 cells against TNF-induced apoptosis (Strelow et al., 2000) . Moreover, inhibition of acid CDase by a newly developed ceramide analogue, B13, induced apoptosis in cultured human colon cancer cells, and prevented liver metastases in vivo (Selzner et al., 2001) .
Liver cancer is the fifth most common cancer in the world and the third cause of cancer-related death. Most patients with hepatocellular carcinoma are diagnosed at intermediate to advanced stages, and effective therapy is not available at present (Block et al., 2003) . Thus, as the balance between ceramide vs S1P determines cell fate and because the role of CDases in hepatocarcinogenesis has not been previously addressed to the best of our knowledge, the aim of our work was to analyse the regulation of individual CDases in hepatoma cells in vitro in response to anthracyclines, and their role on tumor growth in vivo in a murine model of hepatocellular carcinoma.
Results

DNR activates acid CDase in hepatoma cells
Daunorubicin (DNR) has been shown to elicit ceramide generation (Bose et al., 1995; Jaffrezou et al., 1996) , and as ceramide catabolism limits its participation in apoptotic pathways, we determined whether DNR regulates the activities of enzymes that metabolize ceramide. DNR dose dependently caused a rapid and selective activation of acid CDase in HepG2 cells, reaching a maximum at 30 min after drug treatment, without effect on the neutral/alkaline CDases (Figure 1a, b) . In addition, the activity of GCS, which convert ceramide into glucosylceramide, was unchanged by DNR exposure. Real-time polymerase chain reaction (PCR) analyses indicated that DNR did not increase acid CDase mRNA levels, and furthermore, actinomycin D pretreatment did not block the activation of acid CDase by DNR (Supplementary Figure 1) , thus (Figure 2a ). This outcome paralleled the protein level monitored as the acid CDase activity that was reduced 70-80% in HepG2 cells transfected with AC siRNA compared to the activity detected in cells transfected with the scrambled control siRNA (Figure 2b ). In contrast, the activities of the neutral/ alkaline CDase and GCS, however, were unaffected, indicating lack of off-target effects of the AC siRNA ( Figure 2b ). Moreover, HepG2 transfected with AC siRNA displayed enhanced susceptibility to DNRinduced cell death compared with cells transfected with the scrambled control siRNA (Figure 2c ). To examine if acid CDase downregulation regulated ceramide homeostasis after DNR treatment, ceramide levels were measured in AC siRNA-transfected HepG2 cells. Ceramide basal levels (1.870.1 mg/mg protein), moderately increased by DNR treatment, were significantly Acid CDase inhibition by NOE enhances the ceramide to S1P balance and sensitizes hepatoma cells to DNR To evaluate whether N-oleoylethanolamine (NOE), a potent CDase inhibitor (Sugita et al., 1975; Strelow et al., 2000; Monick et al., 2004) recapitulates the effects observed upon acid CDase downregulation, we determined ceramide levels in HepG2 cells in response to DNR with or without acid CDase inhibition by NOE.
In the presence of NOE, which inhibited basal and DNR-induced stimulation of acid CDase in vitro (Supplementary Figure 3a) , DNR enhanced the levels of ceramide with respect to the treatment of cells with DNR alone (Figure 3a ). To examine the metabolic fate of ceramide, we measured the levels of S1P. As seen, the basal content of S1P (4.270.4 pmol/10 6 cells) increased over time in DNR-treated cells and this generation was abolished upon acid CDase inhibition with NOE ( Figure 3b ). Consequently, the ceramide/S1P ratio increased in HepG2 cells following DNR plus NOE treatment with respect to DNR alone ( Figure 3c ). Similar findings were observed with Hepa1c1c7 cells . However, the levels of ceramide or S1P in cells treated with NOE alone did not change over time (Figure 3a, b) . Next, we determined the survival of HepG2 cells treated with DNR plus NOE. As seen, NOE pretreatment enhanced the susceptibility of HepG2 cells to DNR exposure (Figure 3d ), in agreement with the observations using siRNA against acid CDase (Figure 2c ). Similar sensitization to DNR plus NOE was observed in human Hep3B and SK-Hep hepatoma cells or mouse Hepa1c1c7 hepatoma cells (Figure 4a-c) . Interestingly, acid CDase inhibition by NOE did not sensitize cultured mouse hepatocytes to DNR (Figure 3e ), in agreement with previous reports showing the resistance of normal liver cells to B13 treatment (Selzner et al., 2001) . Similar findings with AC siRNA were observed in other hepatoma cell lines but not in cultured mouse hepatocytes ( Figure 5c ). Furthermore, consistent with the lack of activation of the neutral/alkaline CDase by DNR (Figure 1a, b) , its inhibition by D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol (D-MAPP), an alkaline CDase inhibitor with poor activity towards acid CDase (Bielawska et al., 1996) , did not sensitize HepG2 cells to DNR treatment (Figure 3f ). Under these conditions, ). Thus, these results indicate that interfering with ceramide metabolism by reducing acid CDase activity may be a useful strategy to sensitize cancer cells to chemotherapeutic drugs whose mechanism of action involves ceramide generation such as vinblastine or anthracyclines, as opposed to 5-fluorouracil (Bose et al., 1995; Liu et al., 2001) . Paclitaxel cytotoxicity has been related to its ability to increase ceramide levels in sensitive but not in resistant cells (Prinetti et al., 2006) .
S1P protects HepG2 cells against DNR plus NOE
We next tested whether S1P modulated the susceptibility to DNR plus NOE treatment (Cuvillier et al., 1996; Olivera et al., 1999; Spiegel and Milstien, 2003) . Incubation of HepG2 cells with exogenous S1P enhanced intracellular S1P levels (not shown) and protected HepG2 cells against the combination of DNR plus NOE (65 vs 16% survival of DNR þ NOE-treated cells with or without S1P, respectively), with a minor protection against DNR alone (77 vs 68% survival) (Figure 3f ). S1P derives from the phosphorylation of sphingosine by SK, and therefore we tested the effect of dimethyl sphingosine (DMS) an inhibitor of SK (Yatomi et al., 1996; Edsall et al., 1998) on the sensitivity of HepG2 cells to DNR. DMS sensitized HepG2 cells to DNR (Figure 3f ), although to a lesser extent compared to DNR plus NOE. Further, we addressed the sidedness of the protective effect of S1P generated by DNR. It has been reported that S1P elicits its signaling effects either from inside or through its binding to specific S1P receptors (S1PRs) (Payne et al., 2002; Spiegel and Milstien, 2003; Ogretmen and Hannun, 2004) . As some of these S1PRs couple to pertussis toxin-sensitive G proteins to effect cell functions, we tested the role of pertussis toxin on the survival of HepG2 cells following DNR exposure with or without NOE. As seen, pertussis toxin did not sensitize HepG2 cells to DNR or blocked the protective role of extracellular S1P in DNR plus NOE-treated cells (Figure 3f ).
Combination of DNR plus NOE or AC siRNA targets mitochondria We next determined whether DNR plus NOE induced apoptosis via mitochondria (Garcia-Ruiz et al., 1997; Quillet-Mary et al., 1997; Ghafourifar et al., 1999) . The morphological appearance of mitochondria from control HepG2 cells was oval shaped, in association with the endoplasmic reticulum and with organized cristae, and DNR treatment induced minor changes in these organelles (Figure 6a) . However, the combination of DNR plus NOE caused ultrastructural changes in mitochondria displaying aberrant shapes, swollen matrix and disrupted cristae that increased over time (Figure 6a ). The stimulation of DCF fluorescence was observed within 30 min after treatment of cells with DNR plus NOE compared to DNR alone (Figure 6b ). The stimulation of ROS preceded mitochondrial membrane depolarization assessed either by Acid ceramidase in liver cancer treatment A Morales et al tetramethylrhodamine methyl ester (TMRM) labeling or calcein accumulation. TMRM fluorescence decreased over time in HepG2 cells exposed to DNR plus NOE (Figure 6c ). These observations with TMRM were consistent with the distribution of calcein AM, whose mitochondrial accumulation reflects mitochondrial depolarization (Kim et al., 2003) , as DNR plus NOE induced a punctuate pattern of calcein AM fluorescence consistent with mitochondrial staining (Figure 6d ), compared to DNR (Figure 6d ) or NOE alone (not shown). Consistent with these findings, DNR plus NOE stimulated the release of Smac/DIABLO and cytochrome c into the cytosol as soon as 3 h compared with DNR alone (Figure 7a ), and this process was specific for these proteins as confirmed by the levels of cytochrome c oxidase in the cytosol (Figure 7a ). Moreover, in DNR plus NOE-treated cells, we observed the potent activation of caspase-3 monitored by the time-dependent increased fluorescence of Ac-Asp-Glu-Val-Asp-7-amino-4-trifluoromethyl coumarin (AMC) (Figure 7b ). In contrast, minimal caspase-3 activation was detected in cell extracts from DNR-treated HepG2 cells (Figure 7b ). Finally, siRNA-transfected HepG2 cells following DNR treatment resulted in enhanced mitochondrial ROS production, mitochondrial membrane depolarization and caspase-3 activation (Figure 8a-c) , confirming the effects observed with NOE.
RNA interference targeting acid CDase reduces tumor growth in vivo in liver tumor xenografts of HepG2 cells and potentiates DNR therapy
We finally examined if the downregulation of acid CDase by i.v. injection of siRNA could be an effective strategy to reduce in vivo tumor mass in nude mice implanted with intrahepatic orthotopic tumors. Tumor growth was followed by serum alpha-fetoprotein (AFP), a reliable biomarker secreted by hepatocarcinoma cells, which monitors tumor growth in a non-invasive manner. Mice bearing liver tumors were randomly distributed in two separate groups that received AC siRNA or control Sc siRNA treatment every 2 days. AC siRNA treatment selectively decreased acid CDase mRNA in tumor cells without effect on acid CDase mRNA in surrounding healthy parenchyma (Figure 9a ). This outcome translated in reduced acid CDase activity in extracts from tumor mass (Supplementary Figure 4) . Importantly, AC siRNA treatment reduced tumor mass development as measured by AFP levels (Figure 9b) , and confirmed by tumor size measurements. Moreover, the therapeutic effectiveness of AC siRNA was not mediated through enhanced interferon response, as the interleukin (IL)-12 serum levels did not increase with respect to the treatment of mice with Poly I:C, an analog of doublestranded RNA (dsRNA), that is recognized by Toll-Like Receptor 3 (TLR3) and elicits immune responses in mice (not shown). Samples of tumor mass from mice treated with AC siRNA showed enhanced cell apoptosis determined by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end labeling (TUNEL) assay, compared to mice treated with control Sc siRNA (Figure 9c ), indicating that the reduction in tumor mass was associated with enhanced cell death. Finally, we tested the therapeutic combination of AC siRNA and DNR on tumor growth. As seen, the levels of AFP in liver tumor-bearing mice were reduced by AC siRNA and DNR to a greater Acid ceramidase in liver cancer treatment A Morales et al extent than in mice treated with the control siRNA plus DNR (Figure 9d) .
Discussion
The present study shows the post-transcriptional activation of acid CDase by DNR in hepatoma cells as well as in primary cells from murine liver tumors, which results in decreased ceramide accumulation and enhanced S1P formation. These findings imply that the resistance of tumor liver cells to DNR-induced cell death mediated by acid CDase stimulation could be due to decreased ceramide accumulation (upon its deacylation into sphingosine) and/ or enhanced S1P formation (from the phosphorylation of sphingosine). The inhibition of SK by DMS sensitized HepG2 cells to DNR, although to a lesser extent than that caused by DNR plus NOE (Figure 3f ), indicating that although the abolishment of S1P formation by itself contributes to DNR-induced cell death, the accumulation of ceramide combined with the suppression of S1P formation, two consequences of acid CDase inhibition, account for the sensitization of HepG2 cells to DNR.
Although our data are in agreement with previous findings using B13 (Selzner et al., 2001; Ogretmen and Hannun, 2004) or NOE (Hara et al., 2004) to block CDases, it has been reported that primary human SV-40 transformed skin fibroblasts or lymphocytes from Farber disease patients, a genetic disorder characterized by a decrease in acid CDase, were as sensitive to DNRinduced cell death as cells from healthy controls (Burek et al., 2001) . This reported discrepancy with our findings might well be owing to the tumor specificity or type of cells used. The similar response, however, we observed with hepatoma cell lines (human or mouse) and primary cells derived from murine liver tumors indicate that our findings are not related to tumor phenotype, species differences or cumulative chromosomal alterations. Indeed, in hepatoma cell lines, a microarray-based comparative genomic hybridization described that most frequent DNA copy number gain/loss occurred on chromosomes 5, 11, 13, 14 and 17 but not on chromosomes 1 and 8 (Kawaguchi et al., 2005) . Interestingly, acid CDase is located on chromosome 8 (Li et al., 1999) , suggesting that the stimulation of acid CDase is unlikely related to chromosomal modifications. In addition to the decreased ceramide accumulation, acid CDase can protect cells by generating S1P. S1P elicits its survival functions either from inside or outside the cell via specific G protein-coupled S1PRs, some of which are sensitive to pertussis toxin (Payne et al., 2002; Spiegel and Milstien, 2003) . If S1P generated by DNR protected HepG2 cells due to its binding to a subset of S1PRs coupled to pertussis toxin-sensitive G proteins, we would expect that this toxin would sensitize HepG2 cells to DNR. However, this was not the case nor we observed that pertussis toxin abolished the protective effect of extracellular S1P (Figure 3f) . However, at present, we cannot discard the involvement of G proteins-coupled S1PRs insensitive to pertussis toxin.
Our data involve mitochondria in the sensitivity of hepatoma cells to drug-induced cell death. As DNR plus NOE treatment favors ceramide accumulation, it is conceivable that this lipid targets mitochondria eliciting a burst of ROS that precede mitochondrial depolarization and caspase activation. Indeed, the accumulation of ceramide in mitochondria has been reported to mediate tumor necrosis factor (TNF), Fas or radiation-induced cell death (Garcia-Ruiz et al., 1997; Matsko et al., 2001) . In addition, the mitochondrial generation of ceramide upon forced expression of neutral sphingomyelinase in mitochondria leads to apoptotic cell death in MCF7 breast cancer cells (Birbes et al., 2001 ). Although we observed the correlation between enhanced ceramide levels by DNR following acid CDase and mitochondrial structural alterations, it remains to be established whether ceramide directly targeted mitochondria, as shown with GD3 (Garcia-Ruiz et al., 2002) , thus recruiting these organelles to apoptosis signaling or was this mediated by some other mechanism? Furthermore, S1P has been reported to antagonize the release of cytochrome c and Smac/DIABLO from mitochondria and inhibit apoptosis caused by ceramide in human leukemia cells (Cuvillier and Levade, 2001) . Whether ceramide and S1P oppose each other directly in mitochondria or at an upstream level remains to be established.
The mechanism contributing to the stimulation of acid CDase by DNR needs further characterization. Our data indicate that genistein prevented the stimulation of acid CDase by DNR. In line with these findings, previous observations showed that inhibitors of tyrosine kinases, such as genistein, blocked the stimulation of acid CDase by IL-1b (Coroneos et al., 1995; NikolovaKarakashian et al., 1997) . Indeed, acid CDase has at least one tyrosine (Tyr-305) flanked by amino acids that are commonly found in tyrosine phosphorylation sites (Patschinsky et al., 1982) , that is two acidic amino acids (glutamate and aspartate) at positions 2 and 5, and an arginine at position 7. In addition, it is known that anticancer drugs such as DNR stimulate tyrosine kinases (Gruber et al., 2004) . However, further work will be required to examine the mechanisms whereby acid CDase phosphorylation at tyrosine residues results in its activation, without affecting the neutral/ alkaline isoenzyme, and moreover, why this response occurs specifically in tumor hepatocytes but not in primary cells.
Finally, our results show that targeting acid CDase by RNA interference reduces tumor growth in an in vivo model of hepatocellular carcinoma, suggesting that acid CDase activation promotes carcinogenesis and resistance against cancer therapy, suggesting the possibility that deletion of acid CDase, alone or in combination with anticancer drugs, may be of relevance for patients with hepatocellular carcinoma. 
Materials and methods
Cell culture and treatments
The human (HepG2, SK-Hep and Hep-3B) and mouse (Hepa1c1c7) hepatoma cell lines were obtained from the ECACC (Salisbury, Wilts, UK). Hepatocytes from male mice (25-30 g) were prepared by collagenase perfusion and grown in DMEM:F12 on rat tail collagen-coated dishes as described (Colell et al., 2001) . Primary cells from mouse liver tumors induced by HepG2 cells delivery (see below) were obtained by mincing tumor samples followed by collagenase IV (0.5 mg/ml, Sigma) digestion at 371C.
Enzyme activities and ceramide/S1P levels [ 14 C]labeled ceramide was quantified in thin layer chromatography (TLC) plates, and S1P determined by HPLC (Supplementary Methods). Acidic and neutral CDase, and GCS activities were analysed by TLC as detailed in Supplementary Methods online.
Release of cytochrome c, caspase 3 activation and ROS generation The mitochondrial release of cytochrome c and Smac/ DIABLO, caspase 3 activation and ROS generation were determined as reported previously (Paris et al., 2002a) .
Transmission electron microscopy
See Supplementary Methods. In vitro siRNA transfection To silence acid CDase expression, specific predesigned siRNAs (5 0 -AAAATCAACCTATCCTCCTTC-3 0 , human AC siRNA; 5 0 -AACCTATAGAGGACCAGTTCC-3 0 , mouse AC siRNA) and siRNAs with scramble sequences (5 0 -AACCACTCAACT TTTTCCCAA-3 0 , human Sc siRNA; 5 0 -AACAGTTGACCC AGTTGACCA-3 0 , mouse Sc siRNA) were ordered (Curevac, Tu¨bingen, Germany) and transfected in hepatoma cells with siPORT Amine cationic solution (Ambion) according to the manufacturer's instructions. Lipofectamine 2000 was used for siRNA transfection of primary hepatocytes as previously described (Gilot et al., 2005) . Cells were assayed usually 36-72 h after siRNAs duplexes transfection.
Determination of cell death
Orthotopic model of hepatocellular carcinoma and in vivo siRNA treatment All procedures were performed according to protocols approved by the IDIBAPS Ethical Committee. HepG2 cells were injected into the liver of anesthetized 4-5 weeks nude mice. At 2 weeks after tumor cell injection, mice were randomly divided into treatment groups to receive AC siRNA or Sc siRNA, delivered using the hydrodynamic transfection method by i.v. injecting 1 nmols of Sc or AC siRNAs in 1 ml of phosphate-buffered saline (PBS) into the tail vein every 2 days as detailed in Supplementary Methods online.
TUNEL assay and tumor progression After killing of the mice, livers and tumors were fixed and sections (5 mm) stained with hematoxylin and eosin (H&E). TUNEL staining was performed using the In Situ Cell Death Detection Kit (POD) from Roche, examining the slides with a Zeiss Axioplan microscope equipped with a Nikon DXM1200F digital camera. Serum AFP levels were measured by the Centro de Diagnostic Medic (Hospital Clinic, Barcelona, Spain).
Statistics
Results were expressed as mean7standard deviation with the number of individual experiments detailed in figure legends. Statistical significance of the mean values was established by the Student's t-test.
Abbreviations
Ac-DEVD-AMC, Ac-Asp-Glu-Val-Asp-7-amino-4-trifluoromethyl coumarin; Cdases, ceramidases; DCF, 2 0 ,7 0 -dichlorofluorescin; DMS, dimethyl sphingosine; GCS, glucosylceramide synthase; D-MAPP, D-erythro-2-tetradecanoylamino-1-phenyl-1-propanol; NOE, N-oleylethanolamine; NSMase, neutral sphingomyelinase; ROS, reactive oxygen species; SK, sphingosine kinase; S1P, sphingosine-1-phosphate; TMRM, tetramethylrhodamine methyl ester.
